Skip to content

Efficacy of Gemfibrozil as an adjust therapy in obsessive compulsive disorder, a randomized clinical trial with medication control

Efficacy of Gemfibrozil as an adjusted therapy in obsessive-compulsive disorder in patients with obsessive-compulsive disorder

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20230211057389N1
Enrollment
40
Registered
2023-12-10
Start date
2023-12-22
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessives-Compulsive disorder. Obsessive-compulsive personality disorder

Interventions

Intervention 1: Intervention group: The intervention group (20 people) will receive Gemfibrozil (300 mg per day) and Sertraline (100 mg per day) for 8 weeks. Intervention 2: Control group: (20 people

Sponsors

Karaj University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Having DSM-V diagnostic criteria for obsessive-compulsive disorder ages between 18 to 60

Exclusion criteria

Exclusion criteria: Abuse of drugs and medicine except nicotine and caffeine Known case of Mental Retardation Presence of other mental disorders The presence of psychotic manifestations Presence of significant medical or neurological disease (advanced kidney disease, CKD, liver disease, cardiovascular disease, and hypertension) and history of gallstones Concomitant use of warfarin Concomitant use of insulin Concomitant use of Statin group Concomitant use of niacin group drugs

Design outcomes

Primary

MeasureTime frame
Score of Yale-Brown Obsessive-Compulsive scale. Timepoint: Second, fourth and eighth week. Method of measurement: Yale-Brown Obsessive-Compulsive scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSiavash Kianmehr

Karaj University of Medical Sciences

Kianmehrsiavash@gmail.com+98 912 461 1536

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026